FIELD: veterinary medicine.
SUBSTANCE: present invention is a composition of a vaccine against rabies, including IOVB and PIKA adjuvant, as well as their pharmaceutical use. Present invention also relates to a method for preventing or treating a rabies virus infection, comprising the step of administering a rabies vaccine composition to a host.
EFFECT: rabies vaccine composition is more stable and safe and induces earlier and higher neutralizing antibody titers.
38 cl, 5 dwg, 19 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADJUVANT BASED ON POLYINOSINIC ACID-POLYCYTIDYLIC ACID | 2005 |
|
RU2383552C2 |
| IMMUNOGENIC SUBSTANCES CONTAINING ADJUVANT OF POLYINOSINE ACID AND POLYCYTIDYLIC ACID | 2006 |
|
RU2462264C2 |
| COMPOSITION CONTAINING PIC FOR CANCER TREATMENT | 2017 |
|
RU2728175C2 |
| PARAPOXVIRUS VECTOR CONTAINING RABIES VIRUS ANTIGEN | 2011 |
|
RU2545694C2 |
| METHOD FOR PREPARING HIGHLY SPECIFIC HETEROLOGOUS ANTIRABIES SERUM | 2006 |
|
RU2322503C1 |
| VIRUS-LIKE PARTICLES (VLP) OF RABIES VIRUS GLYCOPROTEIN | 2011 |
|
RU2575800C2 |
| VACCINE AGAINST RABIES VIRUS | 2018 |
|
RU2782350C2 |
| COMPLEX FOR ENHANCING IMMUNE RESPONSE | 2019 |
|
RU2779622C2 |
| ANTIRABIC INACTIVATED EMULSION CULTURE VACCINE FOR PROPHYLACTIC IMMUNIZATION OF DOMESTIC CARNIVORES AND FARM ANIMALS | 2019 |
|
RU2722868C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING POLYNUCLEOTIDES, AND USE THEREOF FOR PREVENTING OR TREATING COVID-19 | 2021 |
|
RU2824489C1 |
